Ocumetics Technology (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the company’s ongoing human clinical study of the Ocumetics Lens, its next-generation accommodating intraocular lens.
According to Ocumetics, the Group Two study will evaluate the Ocumetics Lens for safety plus near- and distance-vision performance. The company’s intraocular lens fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses.
In a statement, Dean Burns, president and CEO of Ocumetics, commented “We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter.”
Mr. Burns added, “We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens. At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances.”
